Aug 1, 2011
By:
Jill Wechsler
A number of important decisions from the Supreme Court will affect drug marketing, research, and regulation
|
Jul 1, 2011
By:
Jill Wechsler
Sponsors must handle interchangeability, exclusivity, cost and coverage hurdles to win biosimilars game
|
Jun 1, 2011
By:
Jill Wechsler
FDA's opiod REMS implies there is still value in industry-sponsored CME
|
May 1, 2011
By:
Jill Wechsler
Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies
|
Apr 1, 2011
By:
Jill Wechsler
Courts, Congress review policies and programs shaping drug costs and access
|
Mar 1, 2011
By:
Jill Wechsler
FDA's Sentinel Initiative raises broader questions about tapping patient information and health IT for comparative studies in drug development
|
The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
Feb 1, 2011
By:
Jill Wechsler
The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
|
Director Francis Collins sees NIH as a catalyst for translating biomedical innovations into effective therapies, but skeptics fear it's harder than it looks. It's all in the DNA of its partnerships
Feb 1, 2011
By:
Jill Wechsler
With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?
|
Jan 1, 2011
By:
Jill Wechsler
Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
